Canada · Delayed Price · Currency is CAD BriaCell Therapeutics Company Description
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care.
Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.
The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor.
It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer.
BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers.
The company is headquartered in West Vancouver, Canada.
| Country | Canada |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | William Williams |
Contact Details
Address: Bellevue Centre West Vancouver, BC V7T 2X1 Canada | |
| Phone | 604 921 1810 |
| Website | briacell.com |
Stock Details
| Ticker Symbol | BCT |
| Exchange | Toronto Stock Exchange |
| Fiscal Year | August - July |
| Reporting Currency | USD |
| ISIN Number | CA10778Y3023 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. William V. Williams FCPA, M.D. | Chief Executive Officer, President and Director |
| Gadi Levin B.Com., C.A., CPA, M.B.A. | Chief Financial Officer and Corporate Secretary |
| Dr. Miguel A. Lopez-Lago Ph.D. | Chief Scientific Officer |
| Dr. Giuseppe Del Priore M.D., M.P.H. | Chief Medical Officer |
| Dr. Charles Louis Wiseman FACP, M.D. | Founder, Principal Research Advisor and Member of Scientific Advisory Board |